Leunib
THERAPEUTIC AREA: Oncology / Hematology + Onco-Hematology
ACTIVE PRINCIPLE: Dasatinib
PRESENTATION: 100 mg x 30 coated tablets, 70 mg x 60 coated tablets or 50 mg x 60 coated tablets
INDICATION:
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
COUNTRIES WHERE IT IS MARKETED:
